Literature DB >> 3337903

Clinical factors influencing the efficacy of pooled platelet transfusions.

J F Bishop1, K McGrath, M M Wolf, J P Matthews, T De Luise, R Holdsworth, K Yuen, M Veale, M G Whiteside, I A Cooper.   

Abstract

To determine the relative importance of clinical factors on the efficacy of platelet transfusions, 941 pooled platelet transfusions from HLA-unmatched donors were studied prospectively in 133 patients with bone marrow failure. Multiple linear regression analyses identified the major factors influencing one-hour-corrected increments (CI) as prior splenectomy, bone marrow transplantation, disseminated intravascular coagulation, concurrent intravenous amphotericin B, splenomegaly, and HLA antibody grade. The relative impact of these factors on CI has been quantitated by using a formula developed from these data. A linear relationship was demonstrated between increasing percentage of HLA antibody grade and decreasing CI. A number of other factors were less important in the linear regression model than the aforementioned major factors. These included platelet-specific antibodies, concurrent antibacterial antibiotics, clinical bleeding grade, and temperature. Factors that did not influence CI included the number of prior platelet transfusions, prior granulocyte transfusions, prior red cell transfusions, infection, age, blood group, diagnosis, sex, pretransfusion platelet count, prior pregnancies, and concurrent antineoplastic drugs. This study identified major clinical factors that significantly influenced CI and were major causes of refractoriness to pooled platelet transfusions.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3337903

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

Review 1.  Supportive therapy in management of leukemias.

Authors:  V P Choudhry; N Desai
Journal:  Indian J Pediatr       Date:  1993 Mar-Apr       Impact factor: 1.967

2.  Amphotericin B induced abnormalities in human platelets.

Authors:  K B Pastakia; N E Brownson; D A Terle; B J Poindexter
Journal:  Clin Mol Pathol       Date:  1996-10

3.  Detection and Identification of Platelet-Associated Alloantibodies by a Solid-Phase Modified Antigen Capture Elisa (MACE) Technique and Its Correlation to Platelet Refractoriness in Multi platelet Concentrate Transfused Patients.

Authors:  R S Sarkar; J Philip; Neelesh Jain
Journal:  Indian J Hematol Blood Transfus       Date:  2014-03-29       Impact factor: 0.900

4.  Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients.

Authors:  Sherrill J Slichter; Kathryn Davis; Helen Enright; Hayden Braine; Terry Gernsheimer; Kuo-Jang Kao; Thomas Kickler; Edward Lee; Janice McFarland; Jeffrey McCullough; Glenn Rodey; Charles A Schiffer; Robert Woodson
Journal:  Blood       Date:  2005-02-03       Impact factor: 22.113

5.  Current Status of and Global Trends in Platelet Transfusion Refractoriness From 2004 to 2021: A Bibliometric Analysis.

Authors:  Ying Liu; Yufan Zhang; Dawei Chen; Yongshui Fu
Journal:  Front Med (Lausanne)       Date:  2022-05-06

Review 6.  Transfusion therapy in hemorrhagic shock.

Authors:  Timothy C Nunez; Bryan A Cotton
Journal:  Curr Opin Crit Care       Date:  2009-12       Impact factor: 3.687

Review 7.  Prevention of HLA alloimmunization: role of leukocyte depletion and UV-B irradiation.

Authors:  E L Snyder
Journal:  Yale J Biol Med       Date:  1990 Sep-Oct

8.  Delayed gastric emptying in critical illness: is enhanced enterogastric inhibition with cholecystokinin and peptide YY involved?

Authors:  Andrew J W Samis
Journal:  Crit Care Med       Date:  2008-05       Impact factor: 7.598

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.